187 related articles for article (PubMed ID: 22570527)
1. 111In-labeled cystine-knot peptides based on the Agouti-related protein for targeting tumor angiogenesis.
Jiang L; Miao Z; Kimura RH; Silverman AP; Ren G; Liu H; Lu H; Cochran JR; Cheng Z
J Biomed Biotechnol; 2012; 2012():368075. PubMed ID: 22570527
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a (64)Cu-labeled cystine-knot peptide based on agouti-related protein for PET of tumors expressing alphavbeta3 integrin.
Jiang L; Kimura RH; Miao Z; Silverman AP; Ren G; Liu H; Li P; Gambhir SS; Cochran JR; Cheng Z
J Nucl Med; 2010 Feb; 51(2):251-258. PubMed ID: 20124048
[TBL] [Abstract][Full Text] [Related]
3. Preliminary evaluation of (177)Lu-labeled knottin peptides for integrin receptor-targeted radionuclide therapy.
Jiang L; Miao Z; Kimura RH; Liu H; Cochran JR; Culter CS; Bao A; Li P; Cheng Z
Eur J Nucl Med Mol Imaging; 2011 Apr; 38(4):613-22. PubMed ID: 21153409
[TBL] [Abstract][Full Text] [Related]
4. A novel radiofluorinated agouti-related protein for tumor angiogenesis imaging.
Jiang H; Moore SJ; Liu S; Liu H; Miao Z; Cochran FV; Liu Y; Tian M; Cochran JR; Zhang H; Cheng Z
Amino Acids; 2013 Feb; 44(2):673-81. PubMed ID: 22945905
[TBL] [Abstract][Full Text] [Related]
5. Engineered knottin peptides: a new class of agents for imaging integrin expression in living subjects.
Kimura RH; Cheng Z; Gambhir SS; Cochran JR
Cancer Res; 2009 Mar; 69(6):2435-42. PubMed ID: 19276378
[TBL] [Abstract][Full Text] [Related]
6. Engineered cystine-knot peptides that bind alpha(v)beta(3) integrin with antibody-like affinities.
Silverman AP; Levin AM; Lahti JL; Cochran JR
J Mol Biol; 2009 Jan; 385(4):1064-75. PubMed ID: 19038268
[TBL] [Abstract][Full Text] [Related]
7. A radiofluorinated divalent cystine knot peptide for tumor PET imaging.
Jiang L; Kimura RH; Ma X; Tu Y; Miao Z; Shen B; Chin FT; Shi H; Gambhir SS; Cheng Z
Mol Pharm; 2014 Nov; 11(11):3885-92. PubMed ID: 24717098
[TBL] [Abstract][Full Text] [Related]
8. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression.
Li ZB; Cai W; Cao Q; Chen K; Wu Z; He L; Chen X
J Nucl Med; 2007 Jul; 48(7):1162-71. PubMed ID: 17574975
[TBL] [Abstract][Full Text] [Related]
9. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
10. Specific targeting of human integrin α(v)β (3) with (111)In-labeled Abegrin™ in nude mouse models.
Liu Z; Jia B; Zhao H; Chen X; Wang F
Mol Imaging Biol; 2011 Feb; 13(1):112-20. PubMed ID: 20383594
[TBL] [Abstract][Full Text] [Related]
11. Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature.
Cai W; Chen K; Li ZB; Gambhir SS; Chen X
J Nucl Med; 2007 Nov; 48(11):1862-70. PubMed ID: 17942800
[TBL] [Abstract][Full Text] [Related]
12. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model.
Janssen ML; Oyen WJ; Dijkgraaf I; Massuger LF; Frielink C; Edwards DS; Rajopadhye M; Boonstra H; Corstens FH; Boerman OC
Cancer Res; 2002 Nov; 62(21):6146-51. PubMed ID: 12414640
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetically stabilized cystine knot peptides that bind alpha-v-beta-6 integrin with single-digit nanomolar affinities for detection of pancreatic cancer.
Kimura RH; Teed R; Hackel BJ; Pysz MA; Chuang CZ; Sathirachinda A; Willmann JK; Gambhir SS
Clin Cancer Res; 2012 Feb; 18(3):839-49. PubMed ID: 22173551
[TBL] [Abstract][Full Text] [Related]
14. A dual-labeled knottin peptide for PET and near-infrared fluorescence imaging of integrin expression in living subjects.
Kimura RH; Miao Z; Cheng Z; Gambhir SS; Cochran JR
Bioconjug Chem; 2010 Mar; 21(3):436-44. PubMed ID: 20131753
[TBL] [Abstract][Full Text] [Related]
15. Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide.
Dijkgraaf I; Liu S; Kruijtzer JA; Soede AC; Oyen WJ; Liskamp RM; Corstens FH; Boerman OC
Nucl Med Biol; 2007 Jan; 34(1):29-35. PubMed ID: 17210459
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of 111In-labeled cyclic RGD peptides: tetrameric not tetravalent.
Chakraborty S; Shi J; Kim YS; Zhou Y; Jia B; Wang F; Liu S
Bioconjug Chem; 2010 May; 21(5):969-78. PubMed ID: 20387808
[TBL] [Abstract][Full Text] [Related]
17. alpha(v)beta(3) Integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide.
Yoshimoto M; Ogawa K; Washiyama K; Shikano N; Mori H; Amano R; Kawai K
Int J Cancer; 2008 Aug; 123(3):709-15. PubMed ID: 18498129
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of (111)In-labeled macrocyclic chelator-amino acid derivatives for cancer imaging.
Lee JJ; Shetty D; Lee YS; Kim SE; Kim YJ; Hong MK; Son JY; Jeong JM
Nucl Med Biol; 2012 Apr; 39(3):325-33. PubMed ID: 22136890
[TBL] [Abstract][Full Text] [Related]
19. Comparison of two new angiogenesis PET tracers 68Ga-NODAGA-E[c(RGDyK)]2 and (64)Cu-NODAGA-E[c(RGDyK)]2; in vivo imaging studies in human xenograft tumors.
Oxboel J; Brandt-Larsen M; Schjoeth-Eskesen C; Myschetzky R; El-Ali HH; Madsen J; Kjaer A
Nucl Med Biol; 2014 Mar; 41(3):259-67. PubMed ID: 24417983
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
